You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Revenue rose approximately 30% to $29.3 million as CBLL added 35 hospitals, reaching 747 accounts. It launched delirium monitoring, plans limited Omni release this quarter and a 2027 launch, and raised 2026 revenue guidance to $115 to $117 million.
Ceribell reported revenue growth of 31% and gross margin of 90% for the nine months ended September 30, 2026, while net loss widened 51% and operating cash use was $45,238 thousand.
CeriBell reported third-quarter revenue of $29.3 million, up 30% from 2025, and raised full-year 2026 revenue guidance to $115 million to $117 million. It ended the quarter with 747 active accounts and launched its delirium monitoring solution.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. CeriBell reported Q2 revenue of $28.1M, up 33% year-over-year, and raised full-year 2026 revenue guidance to $114–117M while securing new FDA 510(k) clearances for seizure-detection algorithms and next-generation hardware and refinancing its credit facility.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -9.82M | Three months ended June 30, 2026 filing | — |
| EBITDA (Non-GAAP) non-GAAP | -19.74M | Three months ended June 30, 2026 filing | — |
| IP litigation matter non-GAAP | 3.91M | Three months ended June 30, 2026 filing | — |
| Stock-based compensation non-GAAP | 6M | Three months ended June 30, 2026 filing | — |
| total active accounts | 712 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBLL
this stock
Ceribell, Inc.
|
$1.02B | +19.2% | +36.1% | — | 5.0% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
CeriBell reported third-quarter revenue of $29.3 million, up 30% from 2025, and raised full-year 2026 revenue guidance to $115 million to $117 million. It ended the quarter with 747 active accounts and launched its delirium monitoring solution.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBLL | -1.7% | +4.4% | +39.0% | -1.7% | +19.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.3% | +5.6% | +38.5% | -1.5% | +8.6% |
